Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Retained Earnings (2016 - 2025)

Cytosorbents' Retained Earnings history spans 15 years, with the latest figure at -$312.2 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$312.2 million for Q4 2025, down 2.7% from a year ago — trailing twelve months through Dec 2025 was -$312.2 million (down 2.7% YoY), and the annual figure for FY2025 was -$312.2 million, down 2.7%.
  • Retained Earnings for Q4 2025 was -$312.2 million at Cytosorbents, down from -$3.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $2.3 million in Q4 2022 to a low of -$312.2 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$247.1 million (2022), against an average of -$177.0 million.
  • The sharpest move saw Retained Earnings soared 358.27% in 2022, then tumbled 57533.77% in 2024.
  • Year by year, Retained Earnings stood at -$221.2 million in 2021, then soared by 101.05% to $2.3 million in 2022, then crashed by 77.27% to $529321.0 in 2023, then tumbled by 57533.77% to -$304.0 million in 2024, then decreased by 2.7% to -$312.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$312.2 million, -$3.8 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.